Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 164 results for stroke impact

  1. Social care for older people with multiple long-term conditions (QS132)

    This quality standard covers the planning and delivery of social care and support for older people (aged 65 and over) with multiple long-term conditions. It includes people living in their own homes, in specialist settings or in care homes, both those who receive support with funding for their social care and those who do not. It describes high-quality care in priority areas for improvement.

  2. Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke (DG41)

    Evidence-based recommendations on implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke

  3. Alteplase for treating acute ischaemic stroke (TA264)

    Evidence-based recommendations on alteplase (Actilyse) for treating acute ischaemic stroke in adults.

  4. Stable angina: management (CG126)

    This guideline covers managing stable angina in people aged 18 and over. It outlines the importance of addressing the person’s concerns about stable angina and the roles of medical therapy and revascularisation.

  5. CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack (DG59)

    Evidence-based recommendations on CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack

  6. Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction (TA52)

    Evidence-based recommendations on using thrombolytic drugs (alteplase [Actilyse], reteplase [Rapilysin], streptokinase [Streptase] and tenecteplase [Metalyse]) for treating acute myocardial infarction in adults.

  7. Urinary incontinence in neurological disease: assessment and management (CG148)

    This guideline covers assessing and managing urinary incontinence in children, young people and adults with neurological disease. It aims to improve care by recommending specific treatments based on what symptoms and neurological conditions people have.

  8. Zio XT for detecting cardiac arrhythmias (MTG52)

    Evidence-based recommendations on Zio XT for detecting cardiac arrhythmias.

  9. Dronedarone for the treatment of non-permanent atrial fibrillation (TA197)

    Evidence-based recommendations on dronedarone (Multaq) for treating non-permanent atrial fibrillation in adults.

  10. KardiaMobile for detecting atrial fibrillation (MTG64)

    Evidence-based recommendations on KardiaMobile for detecting atrial fibrillation.

  11. Cardiovascular disease: risk assessment and reduction, including lipid modification (NG238)

    This guideline covers identifying and assessing risk of cardiovascular disease (CVD) in adults without established CVD. It covers lifestyle changes and lipid-lowering treatment (including statins) for primary and secondary prevention of CVD, and includes guidance for people who also have diabetes or chronic kidney disease.

  12. Older people with social care needs and multiple long-term conditions (NG22)

    This guideline covers planning and delivering social care and support for older people who have multiple long-term conditions. It promotes an integrated and person-centred approach to delivering effective health and social care services.

  13. Suspected neurological conditions: recognition and referral (NG127)

    This guideline covers the initial assessment of symptoms and signs that might indicate a neurological condition. It helps non-specialist healthcare professionals to identify people who should be offered referral for specialist investigation.

  14. Ticagrelor for the treatment of acute coronary syndromes (TA236)

    Evidence-based recommendations on ticagrelor (Brilique) for treating acute coronary syndromes in adults.

  15. Atrial fibrillation: admission rates (stroke, not on anticoagulation) (IND39)

    This indicator covers the proportion of patients admitted to hospital for stroke with a pre-existing diagnosis of atrial fibrillation, who were not on anticoagulation. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG56